BDX - Becton Dickinson wins FDA nod for flu COVID RSV combo test

• Becton, Dickinson, and Company ( NYSE: BDX ) announced Wednesday that the FDA issued Emergency Use Authorization (EUA) for a combination test that can detect COVID-19, Influenza, and Respiratory Syncytial Virus (RSV) infections simultaneously.
• The test, designed for use in the company’s BD MAX Molecular Diagnostic System, can deliver results in as little as two hours, based on a single nasal or nasopharyngeal swab sample from the patient, BD ( BDX ) said.
• The authorization is valid only for the detection and differentiation of nucleic acids of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus.
• The company has developed the test using federal funding from the Department of Health and Human Services (HHS).
• Early this week, LumiraDx ( LMDX ) announced it received the EUA for a diagnostic assay that allows the simultaneous detection of COVID-19 and flu viruses.
• Read: BD’s ( BDX ) decision to lift the full-year outlook with its Q1 FY23 results “was a pleasant surprise,” Seeking Alpha contributor Vader Capital argues.

For further details see: